Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-LLT1 monoclonal antibody ZM008

A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) lectin-like transcript-1 (LLT1; CLEC2D; OCIL), with potential immunomodulating and antineoplastic activities. Upon administration, anti-LLT1 monoclonal antibody ZM008 targets and binds to LLT1 expressed on a variety of tumor cells. This prevents the binding of LLT1 to its receptor C-type lectin-like receptor cluster of differentiation 161 (CD161) primarily expressed on CD161-positive natural killer (NK) cells. This prevents CD161-mediated signaling, abrogates the CLEC2D/CD161-mediated suppression of NK cells, leading to the activation and infiltration of NK cells and cytotoxic T cells in the tumor microenvironment (TME) and promotes anti-tumor immune response, thereby enhancing cytotoxicity towards tumor cells. CD161, an inhibitory immune checkpoint, is broadly expressed on NK and a subset of memory CD4+ and CD8+ T cells. LLT1 is expressed on the surface of both malignant cells and various immune cells, including activated B-cells and myeloid cells. The interaction between LLT1 and CD161 leads to immune repressive condition in the TME allowing tumor cells to bypass the human immune system.
Synonym:anti-lectin-like transcript-1 monoclonal antibody ZM008
Code name:ZM 008
ZM-008
ZM008
Search NCI's Drug Dictionary